pre-IPO PHARMA

COMPANY OVERVIEW

EOM Pharmaceuticals is a privately held, clinical-stage company focused on developing novel drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. The Company was founded with a specific vision to pursue innovative and accessible approaches to rescue, repair, and restore health of patients with urgent and unmet medical needs.


LOCATION

  • Montvale, NJ, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Ophthalmology

  • WEBSITE

    https://www.eompharma.com/


    CAREER WEBSITE

    https://www.eompharma.com/contact-us/#team


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Dec 2, 2021

    EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement


    Aug 24, 2021

    EOM Pharmaceuticals Announces First Patients Dosed In R1: RESCUE Phase 1/2a Open-label Trial Evaluating EOM613 In Hospitalized COVID-19 Patients With Severe Symptoms In Brazil España - español Deutschland - English Brazil - Português France - Français Italia - Italiano Deutschland - Deutsch USA - English


    Jul 22, 2021

    EOM Pharmaceuticals Appoints Drug Development Veteran Frank L. Douglas, Ph.D., M.D., Scientific Advisor


    Dec 23, 2020

    EOM Pharmaceuticals Announces Its Pre-IND Meeting Request With U.S. FDA to Evaluate Plans for a Phase 2 Clinical Trial of Its Investigational Dual-Acting, Broad-Spectrum Immunomodulator in COVID-19 Patients


    For More Press Releases


    Google Analytics Alternative